Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT: Roflumilast in COPD Patients on LABA/ICS
NCT01443845Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2011
- Primary completion
- Nov 2015
- Countries
- 17
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast Arm with Placebo Arm (2 arms). Primary endpoint: Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year at 52 weeks. Started Sep 2011; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01443845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01443845.